CoreWeave Inc. said on Tuesday it has struck an agreement to supply Meta Platforms Inc. with up to $14.2 billion of artificial intelligence cloud infrastructure, underscoring the steep costs associated with building and deploying advanced AI models. Shares of CoreWeave jumped more than 13% on market open after the announcement, extending a rally that has
Loading
All posts in "Stock"
CoreWeave Inc. said on Tuesday it has struck an agreement to supply Meta Platforms Inc. with up to $14.2 billion of artificial intelligence cloud infrastructure, underscoring the steep costs associated with building and deploying advanced AI models. Shares of CoreWeave jumped more than 13% on market open after the announcement, extending a rally that has
24Firefly Aerospace shares fell sharply after one of the company’s rockets exploded during testing, raising new concerns about the challenges facing the newly public space technology provider. The stock dropped 23.65% to $28.22 on Tuesday open, following the incident involving the company’s Alpha Flight 7 rocket. Alpha rocket booster destroyed Firefly confirmed that the first
Firefly Aerospace shares fell sharply after one of the company’s rockets exploded during testing, raising new concerns about the challenges facing the newly public space technology provider. The stock dropped 23.65% to $28.22 on Tuesday open, following the incident involving the company’s Alpha Flight 7 rocket. Alpha rocket booster destroyed Firefly confirmed that the first
22Tesla stock edged lower on Tuesday even as Wall Street analysts lifted their price targets, with investors turning their attention to upcoming third-quarter delivery results. The Tesla stock was down 1.3% at $437.09 in early trading, while S&P 500 and Dow Jones Industrial Average futures slipped 0.1% and 0.2%, respectively. The stock is also under
Tesla stock edged lower on Tuesday even as Wall Street analysts lifted their price targets, with investors turning their attention to upcoming third-quarter delivery results. The Tesla stock was down 1.3% at $437.09 in early trading, while S&P 500 and Dow Jones Industrial Average futures slipped 0.1% and 0.2%, respectively. The stock is also under
21The ongoing surge in the Nebius stock price has led to divisions in Wall Street. Many investors believe that it has more room to grow, while others expect it to crumble, citing its hefty valuation. Consequently, its short interest has jumped to nearly 10%. So, is it safe to buy NBIS stock today? The case
The ongoing surge in the Nebius stock price has led to divisions in Wall Street. Many investors believe that it has more room to grow, while others expect it to crumble, citing its hefty valuation. Consequently, its short interest has jumped to nearly 10%. So, is it safe to buy NBIS stock today? The case
46UiPath Inc (NYSE: PATH) opened more than 20% up this morning after the software firm unveiled strategic partnerships with four big names – Nvidia, OpenAI, Google, and Snowflake. The announcement, made during its artificial intelligence (AI) Summit, signals a bold expansion into agentic automation – where AI agents can autonomously execute complex workflows. Investors responded
UiPath Inc (NYSE: PATH) opened more than 20% up this morning after the software firm unveiled strategic partnerships with four big names – Nvidia, OpenAI, Google, and Snowflake. The announcement, made during its artificial intelligence (AI) Summit, signals a bold expansion into agentic automation – where AI agents can autonomously execute complex workflows. Investors responded
23US stock futures showed some gains on Monday, with Dow futures soaring 200 points, as traders tried to shake off last week’s setbacks. After a week of jitters around AI hype cooling off and new tariff threats from the President looming, investors are taking a breath. The S&P 500 and Nasdaq nudged upward, signaling a
US stock futures showed some gains on Monday, with Dow futures soaring 200 points, as traders tried to shake off last week’s setbacks. After a week of jitters around AI hype cooling off and new tariff threats from the President looming, investors are taking a breath. The S&P 500 and Nasdaq nudged upward, signaling a
47Public markets run on rhythm, and if the beat changes, prices move differently. That is what is at stake as the administration pushes to loosen US reporting rules and the SEC is hinting towards a change. The proposal sounds simple enough. It aims to replace mandatory quarterly reporting with the option to report every six
Public markets run on rhythm, and if the beat changes, prices move differently. That is what is at stake as the administration pushes to loosen US reporting rules and the SEC is hinting towards a change. The proposal sounds simple enough. It aims to replace mandatory quarterly reporting with the option to report every six
23Electronic Arts (EA), one of the world’s largest video game publishers, is set to be taken private in a $55 billion deal led by a consortium that includes Saudi Arabia’s Public Investment Fund (PIF), private equity firm Silver Lake, and Affinity Partners, the investment firm founded by Jared Kushner. The deal ranks among the largest
Electronic Arts (EA), one of the world’s largest video game publishers, is set to be taken private in a $55 billion deal led by a consortium that includes Saudi Arabia’s Public Investment Fund (PIF), private equity firm Silver Lake, and Affinity Partners, the investment firm founded by Jared Kushner. The deal ranks among the largest
23Covered call ETFs have become highly popular among income investors in the past few years because of their high distribution rate. The JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) is one of the most popular. This article explores why the QQQI ETF is a better buy. What is the QQQI ETF? The NEOS Nasdaq-100 (R)
Covered call ETFs have become highly popular among income investors in the past few years because of their high distribution rate. The JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) is one of the most popular. This article explores why the QQQI ETF is a better buy. What is the QQQI ETF? The NEOS Nasdaq-100 (R)
34Shares of Swiss biotech MoonLake Immunotherapeutics tumbled 88% to $7.45 in premarket trading on Monday after the company reported mixed outcomes from two late-stage trials of its experimental skin drug, sonelokimab. The treatment is being developed for hidradenitis suppurativa, a painful and chronic inflammatory skin disease. In one of the Phase 3 trials, sonelokimab achieved
Shares of Swiss biotech MoonLake Immunotherapeutics tumbled 88% to $7.45 in premarket trading on Monday after the company reported mixed outcomes from two late-stage trials of its experimental skin drug, sonelokimab. The treatment is being developed for hidradenitis suppurativa, a painful and chronic inflammatory skin disease. In one of the Phase 3 trials, sonelokimab achieved
